ATE262895T1 - Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis - Google Patents

Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis

Info

Publication number
ATE262895T1
ATE262895T1 AT95915254T AT95915254T ATE262895T1 AT E262895 T1 ATE262895 T1 AT E262895T1 AT 95915254 T AT95915254 T AT 95915254T AT 95915254 T AT95915254 T AT 95915254T AT E262895 T1 ATE262895 T1 AT E262895T1
Authority
AT
Austria
Prior art keywords
amyloidosis
treatment
maillard reaction
diseases caused
reaction inhibitors
Prior art date
Application number
AT95915254T
Other languages
English (en)
Inventor
Camilo Colaco
Bruce Joseph Roser
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10753465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE262895(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of ATE262895T1 publication Critical patent/ATE262895T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95915254T 1994-04-13 1995-04-13 Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis ATE262895T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9407305A GB2288732B (en) 1994-04-13 1994-04-13 Pharmaceutical compositions
PCT/GB1995/000843 WO1995028151A1 (en) 1994-04-13 1995-04-13 Use of maillard reaction inhibitors for the treatment of amyloidosis-based disease

Publications (1)

Publication Number Publication Date
ATE262895T1 true ATE262895T1 (de) 2004-04-15

Family

ID=10753465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95915254T ATE262895T1 (de) 1994-04-13 1995-04-13 Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis

Country Status (11)

Country Link
US (2) US5891873A (de)
EP (1) EP0755249B1 (de)
JP (1) JPH09512005A (de)
AT (1) ATE262895T1 (de)
AU (1) AU2219795A (de)
DE (1) DE69532804T2 (de)
DK (1) DK0755249T3 (de)
ES (1) ES2216012T3 (de)
GB (1) GB2288732B (de)
PT (1) PT755249E (de)
WO (1) WO1995028151A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
BR9307141A (pt) * 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
EP0748213B1 (de) * 1994-03-07 2004-04-14 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
KR100384353B1 (ko) * 1994-05-18 2003-10-04 네크타르 테라퓨틱스 인터페론의건조분말제형을제조하기위한방법및조성물
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5780513A (en) * 1996-08-22 1998-07-14 Washington University Method of inhibiting the release of bioactive IL-1
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
JPH1143432A (ja) * 1997-07-25 1999-02-16 Biremo Sci:Kk 脳の老化抑制及び治療剤
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
WO1999039716A1 (fr) * 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Substances preventives et medicaments destines aux maladies neurodegeneratives
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
JP2003531570A (ja) * 1999-07-27 2003-10-28 アブジェニックス インク． 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1888637A2 (de) * 2005-05-19 2008-02-20 Amgen Inc. Zusammensetzungen und verfahren zur erhöhung der stabilität von antikörpern
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
CL2007002881A1 (es) * 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
CN110651043A (zh) 2017-06-07 2020-01-03 天野酶制品株式会社 乳糖酶原料粉末和乳糖酶制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325936A3 (de) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidin-Derivate und für die Maillardreaktion inhibitorische Substanzen, die sie als aktive Inhaltsstoffe enthalten
JPH03161441A (ja) * 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
CA2030718C (en) * 1989-11-28 1998-05-12 Jacob Berger Tricyclic compounds
CA2049940C (en) * 1990-02-19 1996-03-05 Jun Inoue Maillard's reaction inhibitor compositions
SG73414A1 (en) * 1990-03-02 2000-06-20 Oregon State Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ZA92944B (en) * 1991-02-08 1993-08-10 Cambridge Neuroscience Inc Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and methodology for identifying neurotransmitter release blockers
TW221689B (de) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
US5453514A (en) * 1992-12-25 1995-09-26 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors
EP0802797A1 (de) * 1994-02-03 1997-10-29 The Picower Institute For Medical Research Zusammensetzungen und methode zur fortgeschrittenen glycozylierungsprodukte-indurierte modulation des amyloidosis
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions

Also Published As

Publication number Publication date
DE69532804D1 (de) 2004-05-06
GB2288732B (en) 1998-04-29
DK0755249T3 (da) 2004-07-26
EP0755249B1 (de) 2004-03-31
JPH09512005A (ja) 1997-12-02
US6034080A (en) 2000-03-07
GB2288732A (en) 1995-11-01
WO1995028151A1 (en) 1995-10-26
US5891873A (en) 1999-04-06
AU2219795A (en) 1995-11-10
EP0755249A1 (de) 1997-01-29
ES2216012T3 (es) 2004-10-16
PT755249E (pt) 2004-08-31
GB9407305D0 (en) 1994-06-08
DE69532804T2 (de) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE204164T1 (de) Pflaster zur behandlung von nagelmykosen
ATE270556T1 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
DE69428791D1 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
NZ335981A (en) Ketobenzamides as calpain inhibitors
DE69317044D1 (de) Mittel zur regulierung vom hautfettigkeitsgrad
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
DE69929041D1 (de) Verwendung von cabergolin zur behandlung von "restless legs syndrom"
ATE186305T1 (de) Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO996287D0 (no) Chalkoner med antiproliferativ aktivitet
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0755249

Country of ref document: EP

REN Ceased due to non-payment of the annual fee